Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00858663 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00858663: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00858663 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00858663, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the best doses of RAD001 (everolimus) tablets and cisplatin to give to patients who are receiving radiation therapy for head and neck cancer.
Interventions
- RADIATION intensity modulated radiation therapy
- DRUG RAD001 (everolimus) + Cisplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-03 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00858663
The ClinicalTrials.gov registry entry for NCT00858663 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which intensity modulated radiation therapy is the first listed.
NCT00858663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00858663 about?
NCT00858663 is a clinical study titled "Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer". The purpose of this study is to determine the best doses of RAD001 (everolimus) tablets and cisplatin to give to patients who are receiving radiation therapy for head and neck cancer.
What is the current status of trial NCT00858663?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2009-03. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00858663?
The interventions under investigation include: intensity modulated radiation therapy (RADIATION), RAD001 (everolimus) + Cisplatin (DRUG).
Who is sponsoring clinical trial NCT00858663?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.